Inventiva S.A. (EPA: IVA)
France
· Delayed Price · Currency is EUR | Market Cap | 224.66M |
| Revenue (ttm) | 19.28M |
| Net Income (ttm) | -104.19M |
| Shares Out | 87.08M |
| EPS (ttm) | -2.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,944 |
| Open | 2.590 |
| Previous Close | 2.565 |
| Day's Range | 2.575 - 2.630 |
| 52-Week Range | 1.434 - 4.440 |
| Beta | 1.01 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 26, 2025 |
About Inventiva
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, Fra... [Read more]
Financial Performance
In 2023, Inventiva's revenue was 23.16 million, an increase of 23.12% compared to the previous year's 18.81 million. Losses were -110.43 million, 103.5% more than in 2022.
Financial StatementsNews
Alight to Enhance the Employee Experience with Launch of Alight Worklife® on Microsoft Teams
CHICAGO--(BUSINESS WIRE)--Alight is integrating Alight Worklife® with Microsoft Teams, enabling seamless access to benefits and wellbeing info within the Teams platform.
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
Daix (France), Long Island City (New York, United States), November 15, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral...
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH
Daix (France), Long Island City (New York, United States), November 30, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the dev...
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
Daix (France), Long Island City (New York, United States), October 21, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focu...
Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants
Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focu...
Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?
Inventiva SA (NASDAQ: IVA) stock traded higher on Monday, with a strong session volume of 8.55 million compared to an average volume of 9.91k, according to data from Benzinga Pro . The company announ...
Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?
Inventiva SA IVA stock traded higher on Monday, with a strong session volume of 8.55 million compared to an average volume of 9.91k, according to data from Benzinga Pro.
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 47%; Here Are 20 Stocks Moving Premarket
Shares of Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) rose sharply in today's pre-market trading . Lundbeck agreed to acquire Longboard Pharmaceuticals in a transaction valued at approximately $2....
Inventiva secures financing of up to €348M to advance the Nativ3 phase 3 MASH study
Inventiva secures €94.1 million financing for Phase 3 trial of lanifibranor with potential €348 million funding, led by top investors.
Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report
Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focu...
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focu...
Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results
Daix (France), Long Island City (New York, United States), September 25, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the de...
Inventiva Reports Preliminary 2024 First-Half Financial Information¹
Daix (France), Long Island City (New York, United States), July 31, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the develop...
Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor
Daix (France), Long Island City (New York, United States), July 25, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused...
Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux
Daix (France), Long Island City (New York, United States), July 19, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused...
Inventiva announces a €20.1 million issuance of royalty certificates
Daix (France), Long Island City (New York, United States), July 18, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused...
Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement
Inventiva S.A. top-line results from phase 3 NATiV3 study, using lanifibranor for the treatment of patients with MASH, expected by 2nd half of 2026. The 4th pass of the safety review of the DMC was co...
Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position
Daix (France), Long Island City (New York, United States), July 5, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused ...
Results of the votes of the Combined Shareholders' General Meeting of June 20, 2024
Daix (France), Long Island City (New York, United States), on June 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the deve...
Combined General Meeting of June 20, 2024 - Availability of the preparatory documents
Daix (France), Long Island City (New York, United States), May 30, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral smal...
Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024
Daix (France), Long Island City (New York, United States), May 22, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral smal...
Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update
Daix (France), Long Island City (New York, United States), May 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the developm...
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH
Daix (France), Long Island City (New York, United States), May 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the developm...
Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor
Daix (France), Long Island City (New York, United States), May 13, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral smal...
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F
Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the develop...